Kronos Net Working Capital vs Net Debt Analysis
KRON Stock | USD 0.87 0.02 2.25% |
Kronos Bio financial indicator trend analysis is infinitely more than just investigating Kronos Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kronos Bio is a good investment. Please check the relationship between Kronos Bio Net Working Capital and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.
Net Working Capital vs Net Debt
Net Working Capital vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kronos Bio Net Working Capital account and Net Debt. At this time, the significance of the direction appears to have pay attention.
The correlation between Kronos Bio's Net Working Capital and Net Debt is -0.87. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Net Debt in the same time period over historical financial statements of Kronos Bio, assuming nothing else is changed. The correlation between historical values of Kronos Bio's Net Working Capital and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Kronos Bio are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Net Working Capital i.e., Kronos Bio's Net Working Capital and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.87 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Net Working Capital
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Kronos Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kronos Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.As of the 26th of November 2024, Selling General Administrative is likely to drop to about 26.3 M. In addition to that, Sales General And Administrative To Revenue is likely to drop to 5.31
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.7M | 2.3M | 9.2M | 9.6M | Depreciation And Amortization | 236.6K | 2.3M | 2.1M | 1.8M |
Kronos Bio fundamental ratios Correlations
Click cells to compare fundamentals
Kronos Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kronos Bio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 102.7M | 512.0M | 391.5M | 294.9M | 213.3M | 279.9M | |
Short Long Term Debt Total | 528K | 32.1M | 33.8M | 31.1M | 28.3M | 23.2M | |
Other Current Liab | 56K | 6.8M | 1.5M | 11.7M | 8.3M | 5.2M | |
Total Current Liabilities | 2.7M | 12.9M | 13.6M | 21.5M | 24.7M | 14.1M | |
Total Stockholder Equity | (23.2M) | 465.5M | 345.1M | 244.5M | 159.1M | 217.0M | |
Other Liab | 69K | 2.5M | 1.1M | 209K | 240.4K | 228.3K | |
Net Tangible Assets | (23.2M) | 465.5M | 345.1M | 244.5M | 281.2M | 225.4M | |
Property Plant And Equipment Net | 4.2M | 41.0M | 41.8M | 37.7M | 29.9M | 28.7M | |
Net Debt | (32.0M) | (430M) | (305.7M) | (44.9M) | (36.1M) | (37.9M) | |
Retained Earnings | (23.5M) | (111.9M) | (263.0M) | (396.2M) | (508.9M) | (483.4M) | |
Accounts Payable | 1.5M | 4.6M | 998K | 5.0M | 883K | 838.9K | |
Cash | 32.6M | 462.1M | 339.5M | 76.0M | 64.3M | 61.1M | |
Non Current Assets Total | 9.4M | 92.2M | 43.9M | 50.6M | 34.5M | 42.7M | |
Non Currrent Assets Other | 427K | 2.2M | 112.0K | 3.2M | 2.6M | 1.6M | |
Other Assets | 427K | 78.5M | 2.1M | 3.2M | 3.7M | 3.5M | |
Cash And Short Term Investments | 92.2M | 462.1M | 339.5M | 247.9M | 173.0M | 242.9M | |
Common Stock Total Equity | 6K | 54K | 56K | 57K | 65.6K | 39.2K | |
Common Stock Shares Outstanding | 53.0M | 54.1M | 54.8M | 56.2M | 57.7M | 55.8M | |
Short Term Investments | 59.6M | 165.1M | 141.2M | 162.2M | 108.7M | 116.7M | |
Liabilities And Stockholders Equity | 102.7M | 512.0M | 391.5M | 294.9M | 213.3M | 279.9M | |
Non Current Liabilities Total | 123.2M | 33.6M | 32.8M | 29.0M | 29.5M | 35.5M | |
Capital Lease Obligations | 528K | 32.1M | 33.8M | 31.1M | 28.3M | 23.2M | |
Other Current Assets | 1.1M | 5.9M | 8.0M | 5.5M | 5.8M | 4.9M | |
Other Stockholder Equity | (122.6M) | 577.4M | 608.1M | 641.4M | 667.9M | 434.9M | |
Total Liab | 125.9M | 46.4M | 46.4M | 50.4M | 54.2M | 45.8M | |
Net Invested Capital | (23.2M) | 465.5M | 345.1M | 244.5M | 159.1M | 217.0M | |
Property Plant And Equipment Gross | 4.2M | 13.6M | 45.0M | 13.0M | 37.2M | 21.1M | |
Total Current Assets | 93.3M | 419.8M | 347.6M | 244.3M | 178.8M | 237.3M | |
Accumulated Other Comprehensive Income | (18K) | (19K) | (39K) | (792K) | 19K | 20.0K | |
Capital Stock | 6K | 54K | 56K | 57K | 59K | 43.5K | |
Non Current Liabilities Other | 74K | 2.5M | 1.1M | 209K | 240.4K | 228.3K | |
Net Working Capital | 90.6M | 406.9M | 333.9M | 222.8M | 154.1M | 223.2M | |
Short Term Debt | 317K | 942K | 2.1M | 4.7M | 5.8M | 6.1M | |
Common Stock | 6K | 54K | 56K | 57K | 59K | 43.5K | |
Property Plant Equipment | 4.2M | 41.0M | 41.8M | 13.0M | 14.9M | 22.4M |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Kronos Stock
0.71 | ME | 23Andme Holding | PairCorr |
0.72 | VALN | Valneva SE ADR | PairCorr |
0.7 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Kronos Stock
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.